MX2022010248A - Uso de compuesto de nucleosidos en el tratamiento de enfermedades infecciosas por coronavirus. - Google Patents
Uso de compuesto de nucleosidos en el tratamiento de enfermedades infecciosas por coronavirus.Info
- Publication number
- MX2022010248A MX2022010248A MX2022010248A MX2022010248A MX2022010248A MX 2022010248 A MX2022010248 A MX 2022010248A MX 2022010248 A MX2022010248 A MX 2022010248A MX 2022010248 A MX2022010248 A MX 2022010248A MX 2022010248 A MX2022010248 A MX 2022010248A
- Authority
- MX
- Mexico
- Prior art keywords
- infectious diseases
- treatment
- nucleoside compound
- formula
- compound represented
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 2
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title 1
- -1 nucleoside compound Chemical class 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011329 viral nucleic acid test Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
El uso de un compuesto representado por la fórmula (I) o sales farmacéuticamente aceptables del mismo en la preparación de un medicamento para prevenir o tratar una enfermedad infecciosa causada por coronavirus. El compuesto representado por la fórmula (I) se usa para tratar a pacientes con neumonía causada por nuevos coronavirus, y muestra ventajas obvias en la totalidad de la velocidad de aclaramiento por medio de una prueba de ácido nucleico viral, el curso de aclaramiento y el tiempo para la curación y el alta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010125799.2A CN113304166B (zh) | 2020-02-27 | 2020-02-27 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
| PCT/CN2021/077010 WO2021169861A1 (zh) | 2020-02-27 | 2021-02-20 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010248A true MX2022010248A (es) | 2022-10-10 |
Family
ID=77370412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010248A MX2022010248A (es) | 2020-02-27 | 2021-02-20 | Uso de compuesto de nucleosidos en el tratamiento de enfermedades infecciosas por coronavirus. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230277576A1 (es) |
| EP (1) | EP4112050A4 (es) |
| JP (1) | JP7522845B2 (es) |
| KR (1) | KR20220146496A (es) |
| CN (2) | CN116098917A (es) |
| AU (1) | AU2021228008B2 (es) |
| BR (1) | BR112022017209A2 (es) |
| CA (1) | CA3167927A1 (es) |
| IL (1) | IL295840A (es) |
| MA (1) | MA57574A1 (es) |
| MX (1) | MX2022010248A (es) |
| WO (1) | WO2021169861A1 (es) |
| ZA (1) | ZA202210636B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114288313B (zh) * | 2022-02-18 | 2023-07-04 | 常晓宇 | 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途 |
| CN118021821A (zh) * | 2022-03-03 | 2024-05-14 | 苏州旺山旺水生物医药股份有限公司 | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 |
| CN117982522A (zh) * | 2022-11-02 | 2024-05-07 | 河南真实生物科技有限公司 | 核苷类化合物的制药用途 |
| WO2024103016A1 (en) * | 2022-11-11 | 2024-05-16 | Rome Therapeutics, Inc. | 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018030A1 (en) * | 2001-08-24 | 2003-03-06 | Koronis Pharmaceuticals, Inc. | Mutagenic nucleoside analogs for the treatment of viral disease |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| CN100398555C (zh) * | 2003-05-06 | 2008-07-02 | 西托维亚公司 | 冠状病毒和sars-cov的蛋白酶抑制剂及其应用 |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| CN1237185C (zh) * | 2003-06-04 | 2006-01-18 | 中国科学院上海药物研究所 | Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物 |
| PL3597646T3 (pl) * | 2016-08-19 | 2023-12-11 | Gilead Sciences, Inc. | Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV |
| US20190185509A1 (en) * | 2017-12-20 | 2019-06-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10836746B2 (en) * | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI829205B (zh) * | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
-
2020
- 2020-02-27 CN CN202211442145.8A patent/CN116098917A/zh active Pending
- 2020-02-27 CN CN202010125799.2A patent/CN113304166B/zh active Active
-
2021
- 2021-02-20 MX MX2022010248A patent/MX2022010248A/es unknown
- 2021-02-20 JP JP2022551819A patent/JP7522845B2/ja active Active
- 2021-02-20 KR KR1020227030688A patent/KR20220146496A/ko not_active Application Discontinuation
- 2021-02-20 AU AU2021228008A patent/AU2021228008B2/en active Active
- 2021-02-20 US US17/905,142 patent/US20230277576A1/en active Pending
- 2021-02-20 IL IL295840A patent/IL295840A/en unknown
- 2021-02-20 WO PCT/CN2021/077010 patent/WO2021169861A1/zh active Application Filing
- 2021-02-20 BR BR112022017209A patent/BR112022017209A2/pt unknown
- 2021-02-20 MA MA57574A patent/MA57574A1/fr unknown
- 2021-02-20 CA CA3167927A patent/CA3167927A1/en active Pending
- 2021-02-20 EP EP21760199.6A patent/EP4112050A4/en active Pending
-
2022
- 2022-09-26 ZA ZA2022/10636A patent/ZA202210636B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7522845B2 (ja) | 2024-07-25 |
| IL295840A (en) | 2022-10-01 |
| US20230277576A1 (en) | 2023-09-07 |
| CN116098917A (zh) | 2023-05-12 |
| CN113304166B (zh) | 2022-10-14 |
| AU2021228008A1 (en) | 2022-09-22 |
| CN113304166A (zh) | 2021-08-27 |
| ZA202210636B (en) | 2024-01-31 |
| WO2021169861A1 (zh) | 2021-09-02 |
| MA57574A1 (fr) | 2023-11-30 |
| EP4112050A1 (en) | 2023-01-04 |
| EP4112050A4 (en) | 2024-03-20 |
| BR112022017209A2 (pt) | 2022-10-11 |
| JP2023516628A (ja) | 2023-04-20 |
| CA3167927A1 (en) | 2021-09-02 |
| AU2021228008B2 (en) | 2024-08-08 |
| KR20220146496A (ko) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202210636B (en) | Use of nucleoside compound in treatment of coronavirus infectious diseases | |
| JP2023528810A (ja) | レムデシビル治療方法 | |
| CN102438604B (zh) | 高致病性传染性疾病的预防及治疗制剂 | |
| Field et al. | Antibiotic treatment of epidemic bronchiolitis--a double-blind trial. | |
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| WO2008010953A3 (en) | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy | |
| HUP0500558A2 (hu) | Alacsony dózisú entecavir formuláció és eljárás előállítására | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| WO2007106450A3 (en) | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| NO20055512L (no) | Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider | |
| TW202421165A (zh) | 用於治療病毒感染之方法 | |
| WO2023142800A1 (zh) | 盐酸多塞平在制备抗病毒药物中的应用 | |
| CN113368121A (zh) | 抗冠状病毒的连翘苷和连翘脂素组合物 | |
| CN204744378U (zh) | 一种四肢长骨抗感染内固定装置 | |
| RU2554495C2 (ru) | Цитокинсодержащее лекарственное средство, обладающее противовирусным, противомикробным, иммуномодулирующим и противовоспалительным действием для профилактики и лечения инфекционных заболеваний | |
| RU2014138880A (ru) | Введение эриторана или его фармацевтически приемлемых солей для лечения ортомиксовирусных инфекций | |
| GEP20227432B (en) | Therapy of high-risk human papillomavirus infections | |
| KR20000005479A (ko) | 약독화된 비면역원성 폭스 바이러스 또는 파라폭스 바이러스로부터 멀티포텐트 파라폭스 면역 유발인자의 약제로서 이용하는새로운 적용 | |
| RU2480219C1 (ru) | Способ лечения оспы | |
| Sun | Pathogen infection recovery probability (PIRP) versus proinflammatory anti-pathogen species (PIAPS) levels: modelling and therapeutic strategies | |
| CN117731666A (zh) | 一种石蒜碱氧酯及其盐在制备广谱抗冠状病毒药物中的应用 | |
| Башурова et al. | DIAPHRAGMATIC HERNIA: A GIANT LARREY'S HERNIA (CLINICAL CASE) | |
| Hedvat et al. | 2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis | |
| Lola et al. | THE EFFECT OF HEPATOPROTECTORS ON THE FUNCTIONAL STATE OF THE LIVER IN PATIENT UNDERWENT TO COVID-19 |